Rising Bacterial Infection and Demand for Affordable Treatment is Expected to Propel the Growth of Resistant Pseudomonas Aeruginosa Infections Drugs Market

The global resistant pseudomonas aeruginosa infections drugs market is anticipated to grow at a considerable CAGR of 4.5% during the forecast period (2022-2028). Due to the increased prevalence of hospital-acquired infections (HAIs) caused by multi-drug resistant Pseudomonas aeruginosa strains, anti-resistance pseudomonas aeruginosa drugs are in high demand. Furthermore, following COVID-19, public awareness of antimicrobial infections has increased, as has need for treatment. With the introduction of enhanced medications and therapies, the sector is also witnessing technical advancements that will boost the market during the forecast period.

Browse the full report description “Global Resistant Pseudomonas Aeruginosa Infections Drugs Market Size, Share & Trends Analysis Report by Type (Semi-Synthetic Penicillin, Cephalosporin, and Lactam Drugs), and by Application (Hospital and Clinic, and Home Care) Forecast 2022-2028” at https://www.omrglobal.com/industry-reports/resistant-pseudomonas-aeruginosa-infections-drugs-market

The key companies operating in the industry are highly inclined towards the adoption of different growth strategies including capacity expansion, partnerships, mergers and acquisitions, geographical expansion, new product launch, and product innovation to remain competitive in the marketplace. For instance, Zydus Cadila Healthcare Ltd. manufactures Orizolin in the form of injection in the market in three quantities of 1gm, 250mg, and 500mg. Cefazolin is an antibiotic that is used to treat bacterial infections. It's used before procedures to prevent bacterial infections afterward. Further, Ranbaxy Laboratories Ltd. manufacturers Reflin in the form of Injections in the market in four quantities of 1gm, 250mg, 500mg, and 1g. Reflin Injection is an antibiotic that works by killing the bacteria that cause infections in the body. It treats bacterial infections of the mouth, throat, ears, urinary tract, skin, and soft tissues.  

Market Coverage

• The market number available for – 2021-2028
• Base year- 2021
• Forecast period- 2022-2028

Segment Covered- 

• By Type
• By Application

Regions Covered-

• North America
• Europe
• Asia-Pacific
• Rest of the World

Competitive Landscape- including AbbVie Inc., Bristol Myers Squibb Co., Biolytics Pharma, ContraFect Corp., Novartis AG, and others.

Key questions addressed by the report

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• How COVID-19 impacted the market?

o Deviation from the pre-COVID-19 forecast

o Most affected region and segment

• Who is the leader in the market?
• How are players addressing challenges to sustain growth?
• Where is the investment opportunity?

Global Resistant Pseudomonas Aeruginosa Infections Drugs Market Report Segment

By Type

• Semi-Synthetic Penicillin
• Cephalosporin
• Lactam Drugs

By Application

• Hospital and Clinic
• Home Care

Global Resistant Pseudomonas Aeruginosa Infections Drugs Market Report Segment by Region

North America

• US
• Canada

Europe

• UK
• Germany
• Italy
• Spain
• France
• Rest of Europe 

Asia-Pacific

• China
• India
• Japan
• South Korea
• Rest of Asia-Pacific 

Rest of the World

• Latin America 
• Middle East & Africa